IGF-1 LR3: Long-Acting Insulin-Like Growth Factor

IGF-1 LR3 (Long R3 IGF-1) is a modified form of human insulin-like growth factor 1 in which the glutamic acid at position 3 is replaced with arginine (E3R substitution) and a 13-amino acid N-terminal extension peptide is added. The resulting 83-amino acid protein has a molecular weight of approximately 9,111 Da.

These modifications were engineered to reduce the affinity of IGF-1 for insulin-like growth factor binding proteins (IGFBPs). In native physiology, over 99% of circulating IGF-1 is bound to IGFBPs (primarily IGFBP-3 in a ternary complex with ALS), which regulate IGF-1 bioavailability, half-life, and tissue distribution. By escaping IGFBP sequestration, IGF-1 LR3 has a significantly greater proportion of free, biologically active growth factor.

IGF-1 LR3 was originally developed for use in serum-free cell culture media, where it provides sustained growth factor signaling without the confounding effects of serum-derived IGFBPs. It has since become a widely used research tool in cell biology, tissue engineering, and growth factor signaling studies.

The IGF system is one of the most important growth factor pathways in mammalian biology.

**Components:** The system comprises two ligands (IGF-1 and IGF-2), two receptors (IGF-1R and IGF-2R/mannose-6-phosphate receptor), six high-affinity binding proteins (IGFBP-1 through IGFBP-6), and IGFBP proteases that regulate binding protein levels.

**IGF-1 receptor signaling:** IGF-1 binds the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase structurally related to the insulin receptor. Ligand binding triggers receptor autophosphorylation and activation of two major downstream pathways: the PI3K/Akt pathway (cell survival, metabolism, protein synthesis) and the Ras/MAPK/ERK pathway (cell proliferation, differentiation). The PI3K/Akt/mTOR axis is particularly important for IGF-1's effects on protein synthesis and cell growth.

**IGFBP regulation:** IGFBPs regulate IGF bioavailability through high-affinity binding (Kd in the nanomolar range). They can both inhibit IGF action (by sequestering ligand away from the receptor) and potentiate it (by concentrating IGF near target cells and releasing it through IGFBP proteolysis). This dual role makes IGFBP biology complex but essential for understanding IGF physiology.

**GH-IGF-1 axis:** In vivo, IGF-1 production is primarily regulated by growth hormone, with the liver producing the majority of circulating IGF-1. Local (autocrine/paracrine) IGF-1 production occurs in many tissues and is regulated by tissue-specific factors independent of GH.

The two structural changes in IGF-1 LR3 each serve a specific purpose:

**E3R substitution:** Replacing glutamic acid with arginine at position 3 disrupts a key contact point between IGF-1 and IGFBP-3 (the primary circulating binding protein). This single amino acid change reduces IGFBP-3 affinity by approximately 100-fold while preserving full IGF-1 receptor binding and activation.

**13-amino acid N-terminal extension:** The extension peptide further disrupts IGFBP interactions by sterically hindering the N-terminal binding interface. It also slightly alters the three-dimensional presentation of the mature IGF-1 domain to IGFBPs without affecting IGF-1R engagement.

**Net effect:** IGF-1 LR3 activates the IGF-1 receptor with potency similar to native IGF-1 (approximately equivalent EC50 in receptor phosphorylation assays) but remains predominantly free in biological fluids rather than bound to IGFBPs. This results in a higher effective concentration of bioactive growth factor and a more sustained signaling response in cell culture and in-vivo models.

**Practical consequence for researchers:** In cell culture, replacing native IGF-1 with IGF-1 LR3 allows the use of lower total growth factor concentrations to achieve equivalent biological effects, because the active fraction is much higher. This is particularly valuable in serum-free or low-serum culture conditions where IGFBP levels are controlled.

IGF-1 LR3 is used across a broad range of cell biology and tissue research contexts.

IGF-1 LR3 is a protein growth factor requiring careful handling:

**Reconstitution:** Reconstitute in 10 mM HCl or the buffer specified by the manufacturer. IGF-1 LR3 is an acidic protein and may aggregate at neutral pH in the absence of carrier protein. For neutral-pH applications, add BSA (0.1%) or other carrier to prevent adsorption and aggregation.

**Cell culture concentrations:** Typical working concentrations are 20-100 ng/mL for proliferation support and 50-200 ng/mL for differentiation and signaling studies. These concentrations are lower than those needed for native IGF-1 because more of the growth factor remains free and receptor-available.

**Signaling assays:** For acute signaling studies (receptor phosphorylation, Akt/ERK activation), treat serum-starved cells with IGF-1 LR3 for 5-30 minutes. For proliferation assays (BrdU, Ki67), 24-72 hours of continuous exposure is standard. For differentiation assays, longer protocols (5-14 days) with regular media changes are typical.

**Storage:** Lyophilized IGF-1 LR3 is stable at -20°C for 12-24 months. Reconstituted solutions should be stored at 2-8°C for short-term use (up to 7 days) or aliquoted and frozen at -80°C with carrier protein for longer storage. Avoid repeated freeze-thaw cycles.

**Controls:** Use native IGF-1 as a comparator to distinguish IGFBP-dependent from IGFBP-independent effects. Use an IGF-1R tyrosine kinase inhibitor (e.g., BMS-754807) or IGF-1R neutralizing antibody as a negative control to confirm receptor dependence.

*All materials are for research use only.*